Premium
Expression of programmed death‐1 in skin biopsies of benign inflammatory vs. lymphomatous erythroderma
Author(s) -
Çetinözman F.,
Jansen P.M.,
Willemze R.
Publication year - 2014
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.12934
Subject(s) - erythroderma , cd8 , pathology , medicine , psoriasis , cytotoxic t cell , t cell , skin biopsy , biopsy , immunology , biology , immune system , in vitro , biochemistry
Summary Background Histological differentiation between Sézary syndrome ( SS ) and erythrodermic inflammatory dermatoses ( EID ) can be very difficult. Recent studies show that programmed death‐1 ( PD ‐1) is strongly expressed by the neoplastic cells in skin biopsies of SS , while similar studies in EID are lacking. Objectives To determine whether the number and distribution of PD ‐1 + T cells could be used as an adjunct in the differentiation between SS and EID . Methods Expression of PD ‐1 and a panel of T‐cell markers was investigated in skin biopsies from 30 patients with various types of EID (12 idiopathic, 10 atopic, six psoriatic and two paraneoplastic) and 25 patients with SS . Results Expression of PD ‐1 by > 50% of the infiltrating T cells was observed in 23 of 25 (92%) SS cases and in only four of 30 (13%) EID cases. PD ‐1 is expressed by neoplastic CD 4 + T cells in SS , while in contrast, PD ‐1 was predominantly expressed by dermal and epidermal CD 8 + T cells in EID . Expression of CD 7 by ≤ 20% of the infiltrating T cells was observed only in SS (13 of 24; 54%), and not in any of the 30 cases of EID . Conclusions While PD ‐1 is expressed by CD 4 + neoplastic T cells in SS , our results suggest that PD ‐1 is expressed mainly by activated dermal and epidermal CD 8 + T cells in EID . Expression of PD ‐1 by > 50% of CD 4 + T cells and expression of CD 7 by ≤ 20% of the infiltrating T cells strongly support a diagnosis of SS in skin biopsies of patients with erythroderma.